Pioneering a new approach for treating snakebite

    Pioneering a new approach for treating snakebite

      Pioneering a new approach for treating snakebite

        Pioneering a new approach for treating snakebite

          Learn More

          Nothing has really changed in how snakebites have been treated for over 100 years. Our goal is to change that now.”
          -Jeremy Gowler, CEO & Board Director

          Learn More
          Image

          Adapted from Figure 6 in: Escalante T, Ortiz N, Rucavado A, Sanchez EF, Richardson M, Fox JW, et al. (2011) Role of Collagens and Perlecan in Microvascular Stability: Exploring the Mechanism of Capillary Vessel Damage by Snake Venom Metalloproteinases. PLoS ONE 6(12): e28017. https://doi.org/10.1371/journal.pone.0028017. Licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Arrows removed for clarity and image quality and color is adjusted and enhanced using AI

          Learn More

          Ophirex’s lead candidate is varespladib, a small-molecule inhibitor of snake venom secretory phospholipase A2 (sPLA2), a class of toxins present in the venom of 95% of snake species. An oral treatment for snakebite could reduce the time to treatment from hours to minutes.

          Learn More